These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29239232)

  • 1. Effectiveness of Single- and Multiple-Tablet Antiretroviral Regimens in Correctional Setting for Treatment-Experienced HIV Patients.
    Merker A; Badowski M; Chiampas T; Pérez SE; Patel M; Young J; Werner R
    J Correct Health Care; 2018 Jan; 24(1):52-61. PubMed ID: 29239232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.
    Scott Sutton S; Magagnoli J; Hardin JW
    Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Odds of Viral Suppression by Single-Tablet Regimens, Multiple-Tablet Regimens, and Adherence Level in HIV/AIDS Patients Receiving Antiretroviral Therapy.
    Sutton SS; Magagnoli J; Hardin JW
    Pharmacotherapy; 2017 Feb; 37(2):204-213. PubMed ID: 28028855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence among rural HIV-infected patients in the deep south: a comparison between single-tablet and multi-tablet once-daily regimens.
    Tennant SJ; Hester EK; Caulder CR; Lu ZK; Bookstaver PB
    J Int Assoc Provid AIDS Care; 2015; 14(1):64-71. PubMed ID: 25331217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients.
    Rwagitinywa J; Lapeyre-Mestre M; Bourrel R; Montastruc JL; Sommet A
    Fundam Clin Pharmacol; 2018 Aug; 32(4):450-458. PubMed ID: 29505661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naïve patients.
    Hemmige V; Flash CA; Carter J; Giordano TP; Zerai T
    AIDS Care; 2018 Aug; 30(8):1017-1024. PubMed ID: 29478329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
    Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
    Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost considerations in the current antiretroviral era.
    Eaton EF; Tamhane A; Saag M; Mugavero MJ; Kilgore ML
    AIDS; 2016 Sep; 30(14):2115-9. PubMed ID: 27088319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship Between Single Tablet Antiretroviral Regimen and Adherence to Antiretroviral and Non-Antiretroviral Medications Among Veterans' Affairs Patients with Human Immunodeficiency Virus.
    Yager J; Faragon J; McGuey L; Hoye-Simek A; Hecox Z; Sullivan S; Neubert S; Patel N
    AIDS Patient Care STDS; 2017 Sep; 31(9):370-376. PubMed ID: 28771023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components.
    Llibre JM; de Lazzari E; Molina JM; Gallien S; Gonzalez-García J; Imaz A; Podzamczer D; Clotet B; Domingo P; Gatell JM
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 Jan; 36(1):16-20. PubMed ID: 27595183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.
    Arribas JR; DeJesus E; van Lunzen J; Zurawski C; Doroana M; Towner W; Lazzarin A; Nelson M; McColl D; Andreatta K; Swamy R; Szwarcberg J; Nguyen T
    HIV Clin Trials; 2017 May; 18(3):118-125. PubMed ID: 28555519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence after treatment switch from a multiple tablet antiretroviral regimen to a single tablet antiretroviral regimen.
    Sutton SS; Magagnoli J; H Cummings T; Hardin JW
    Therapie; 2021; 76(6):567-576. PubMed ID: 33589316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
    Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
    AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.
    Gianotti N; Poli A; Nozza S; Spagnuolo V; Tambussi G; Bossolasco S; Cinque P; Maillard M; Cernuschi M; Galli L; Lazzarin A; Castagna A
    J Int AIDS Soc; 2015; 18(1):20037. PubMed ID: 26232000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
    Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S
    Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks.
    Sutton SS; Hardin JW; Bramley TJ; D'Souza AO; Bennett CL
    Am J Manag Care; 2016 Apr; 22(4):242-8. PubMed ID: 27143289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.